The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program
Related Resources
All Resources
post
Why FDA PreCheck is a game-changer for small & mid-sized pharma — and how these companies should lean in
Read More
white-paper
Solid-Phase Oligonucleotide Synthesis (SPOS) and Liquid-Phase Oligonucleotide Synthesis (LPOS): Complementary or Competitive Processes?
Read More
post
The Startup’s Guide: 10 Must-Have CMC SOPs for Virtual Pharma in Phase 1
Read More
white-paper
The CMC Trap: How Chemistry, Manufacturing, and Controls Failures Derail Drug Development
Read More
Let's move from science to success.
Let’s Talk